Across TCGA pan-cancer cohorts, ADPRS Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ADPRS data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ADPRS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADPRS expression acts as an unfavorable survival marker.
BRCA and UCS are the cancer types where ADPRS Mutation most reproducibly stratifies survival.